Loading
Life sciences · Journal article
International Journal of Nanomedicine · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract: The clinical translation of cancer nanomedicine remains constrained by inefficient intracellular delivery, poor subcellular specificity, and limited tumor accumulation, highlighting the need for more precise drug delivery strategies. Organelle-targeted nanocarriers have emerged as a promising platform for enhancing therapeutic efficacy by directing drugs to specific intracellular compartments, including the nucleus, mitochondria, lysosomes, and endoplasmic reticulum. However, the design principles governing efficient organelle-specific delivery and the barriers limiting clinical translation remain incompletely understood. This review provides a mechanistic framework linking nanoparticle physicochemical properties-including size, surface charge, ligand functionalization, and stimuli responsiveness to intracellular trafficking, organelle targeting, and therapeutic performance. We critically discuss the biological barriers encountered during delivery, including cellular uptake, endosomal escape, cytosolic transport, and organelle membrane penetration, together with current engineering strategies to overcome these challenges. Organelle-specific targeting approaches are comparatively evaluated to highlight their therapeutic advantages, limitations, and suitable clinical applications. Beyond summarizing recent advances, this review examines the major translational hurdles that impede clinical implementation, including non-specific biodistribution, manufacturing scalability, regulatory challenges, and the lack of standardized preclinical evaluation models. Emerging solutions such as hierarchical targeting, charge-reversal systems, size-transformable nanocarriers, and multifunctional theranostic platforms are discussed as strategies to improve clinical feasibility. Finally, we propose practical design guidelines and future research priorities that integrate nanomaterial engineering, predictive biological models, and scalable manufacturing to facilitate the development of clinically translatable organelle-targeted nanomedicines. Keywords: cancer treatment, organelle-targeted nucleus therapy, organelle-targeted mitochondrion therapy, nano-drugs, endoplasmic reticulum, lysosome, golgi apparatus